|

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

RECRUITINGPhase 3Sponsored by Clarity Pharmaceuticals Ltd
Actively Recruiting
PhasePhase 3
SponsorClarity Pharmaceuticals Ltd
Started2023-12-21
Est. completion2026-09
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
Locations20 sites
View on ClinicalTrials.gov →

NCT06056830

Summary

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

Eligibility

Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* At least 18 years of age.
* Signed informed consent.
* Untreated, histologically confirmed adenocarcinoma of the prostate.
* High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.202327 (clinical stage ≥T3a, or Grade Group ≥4, or PSA \>20 ng/mL).
* Patients electing to undergo RP with PLND.

Exclusion Criteria:

* Administration of any high energy (\>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1.
* Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components.
* Patients with known predominant small cell or neuroendocrine PC.

Conditions3

CancerProstate CancerProstatic Neoplasms

Locations20 sites

Mayo Clinic- Phoenix
Phoenix, Arizona, 85054
Jack Andrews, MD
Greater Los Angeles VA Medical Center
Los Angeles, California, 90073
Gholam R. Berenji, MD
Stanford University Medical Center
Stanford, California, 94305-5105
Hong Song, MD, PhD
Mayo Clinic- Jacksonville
Jacksonville, Florida, 32224
Ephraim Parent, MD
NorthShore University Health System
Glenview, Illinois, 60026
Brian Helfand, MD

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.